PenderFund Capital Management’s Atrium Therapeutics RNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.23K Sell
390
-100
-20% -$1.18K ﹤0.01% 231
2026
Q2
$6.59K Hold
490
– – ﹤0.01% 217
2026
Q1
$6.55K Buy
+490
New +$6.88K ﹤0.01% 220

Other funds holding RNA

PenderFund Capital Management's RNA Position: Q3 2026 in Review

PenderFund Capital Management reduced its Atrium Therapeutics (RNA) stake by 20% in Q3 2026, selling an estimated $1.18K and leaving 390 shares worth $3.23K. The position accounts for ﹤0.01% of the portfolio, ranked #231.

PenderFund Capital Management first reported a position in RNA in Q1 2026 and has held it in 3 quarters since. The position peaked at $6.59K in Q2 2026. 148 funds tracked by Wall St. Rank hold RNA as of Q3 2026.

  • PenderFund Capital Management held 390 shares of Atrium Therapeutics worth $3.23K as of Q3 2026.
  • PenderFund Capital Management sold 100 Atrium Therapeutics shares in Q3 2026, an estimated $1.18K.
  • Atrium Therapeutics made up ﹤0.01% of PenderFund Capital Management's portfolio in Q3 2026, its #231 holding.
  • PenderFund Capital Management first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • PenderFund Capital Management's Atrium Therapeutics position peaked at $6.59K in Q2 2026.
  • 148 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.

Based on PenderFund Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.